A Pilot Study of Daunorubicin-cytarabine Liposome (CPX-351) Plus FLT3-inhibitor (Midostaurin) as Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia Followed by Consolidation With a CD34+-Selected Allograft
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Midostaurin (Primary) ; Busulfan; Fludarabine; Melphalan
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 01 Oct 2024 Status changed from recruiting to withdrawn prior to enrolment. (Could not accrue)
- 27 Jul 2022 Status changed from not yet recruiting to recruiting.
- 27 May 2022 Planned initiation date changed from 15 Apr 2022 to 1 Jul 2022.